anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A method and system for assessing a machine learning model providing a prediction as to the disease state of a patient from a 2D or 3D image of the patient or a sample obtained therefrom. The machine learning model produces a prediction of the disease state from the image. The method involves presenting on a display of a workstation the image of the patient or a sample obtained therefrom along with a risk score or classification associated with the prediction. The image is further augmented with highlighting to indicate one or more regions in the image which affected the prediction produced by the machine learning model. Tools are provided by which the user may highlight one or more regions of the image which the user deems to be suspicious for the disease state. Inference is performed on the user-highlighted areas by the machine learning model. The results of the inference are presented to the user via the display.
In clinical trials of LEVEMIR, 64 of 1624 patients (4%) in the type 1 diabetes trials and 309 of 1082 patients (29%) in the type 2 diabetes trials were 65 years or older. A total of 52 (7 type 1 and 45 type 2) patients (2%) were 75 years or older. No overall differences in safety or effectiveness were observed between these patients and younger patients, but small sample sizes limits conclusions. Greater sensitivity of some older individuals cannot be ruled out. In geriatric patients, the initial dosing, dosage increments, and maintenance dosage should be conservative to avoid hypoglycemia. Hypoglycemia may be difficult to recognize in the geriatric patients.
Chronic graft-versus-host-disease (cGVHD) is divided into two subtypes: classic (absence of acute GVHD features) and overlap cGVHD ('ocGVHD'), in which both chronic and acute GVHD clinical features are present simultaneously. While worse outcomes with ocGVHD have been reported, there are few recent analyses. We performed a secondary analysis of data from the ABA2 trial (N = 185), in which detailed GVHD data were collected prospectively and systematically adjudicated. Analyses included cumulative incidence of classic versus ocGVHD, their specific organ manifestations, global disease severity scores, non-relapse mortality (NRM), disease-free survival (DFS) and overall survival (OS) in these two cGVHD subtypes. Of 92 patients who developed cGVHD, 35 were classified as ocGVHD. The 1-year cumulative incidence, organ involvement, and global severity of classic and ocGVHD were similar between ABA2 patients receiving CNI/MTX+placebo and CNI/MTX+abatacept; thus, cohorts were combined for ocGVHD evaluation. This analysis identified ocGVHD as having significantly higher severity at presentation and at maximum global severity compared to classic cGVHD. OS and DFS were significantly lower for ocGVHD versus classic cGVHD. OcGVHD is associated with increased cGVHD severity scores, and is associated with decreased OS and DFS compared to classic cGVHD, underscoring the high risks with this cGVHD subtype.
This is a Phase 2 multicenter, controlled, randomized, double-blind study to evaluate the efficacy and safety of ficlatuzumab versus placebo when administered with erlotinib in subjects with previously untreated metastatic EGFR-mutated NSCLC and BDX004 Positive Label.

Prior to screening, subjects will have tested positive for a sensitizing EGFR mutation to determine eligibility for treatment with erlotinib. During screening, subject serum samples will be tested using the investigational companion diagnostic (BDX004) test. Only those subjects who have a BDX004 Positive Label will be enrolled. Subject randomization will be stratified by EGFR mutation type and smoking status (ever versus never smokers). Subjects will be designated as never smokers if they have smoked less than 100 cigarettes in their lifetime. Radiographic tumor assessment, to include CT or MRI of chest and abdomen, will be performed every 4 weeks for the first 8 cycles, and every 8 weeks thereafter, using the same imaging modality per subject. Safety assessments will be performed on an ongoing basis.
1,230,472. Acth preparations. CIBA-GEIGY A.G. 1 July, 1968 [10 July, 1967], No. 31283/ 68. Heading A5B. A pharmaceutical preparation suitable for resorption through the mucous membranes of the mouth or nose comprises an adreno-corticotropically active peptide in the form of a non-aqueous suspension or solution comprising a suspending agent or solvent selected from; monoesters of C 2-3 alkanols or sorbitan polyoxyethylene glycols with C 8-22 fatty acids, diesters of polyoxyethyleneglycols and triesters of glycerol, with fatty acids having 8-22 carbon atoms and 8-12 carbon atoms respectively, or mixtures thereof. The active compound may be a natural corticotrophin or a synthetic peptide having a shorter amino acid chain which may be varied insofar as individual amino acids are concerned. Numerous examples of the synthetic peptides are given. Preferred forms are nasal sprays and self-propelled aerosol compositions.
[GB1230472A]
The intervention facilities will provide IMCI services with PO in addition to following existing IMCI guidelines. The IMCI service providers will classify and treat children presenting with cough and difficult breathing based on history and clinical signs. In addition, they will use PO to measure the SpO2 status of the sick children. Children clinically classified as 'Pneumonia' but having SpO2\<90% will be referred to higher-level facilities for in-patient management. Only the children clinically classified 'Pneumonia' and having SpO2\>90% will be treated through home-based management with oral antibiotics (amoxicillin, twice daily for five day).
The goal of this project is to conduct a Phase I clinical trial to determine the recommended Phase II dose (RP2D) of bladder cancer-targeting micelles loaded with a chemotherapeutic drug paclitaxel (PTX). The investigators previously developed a bladder cancer-specific targeting ligand named PLZ4, and a PLZ4-coated PTX-loaded nanoscale micelle (PPM) platform that can specifically deliver the drug load into bladder cancer cells both in vitro and in vivo. This proposed clinical trial is to conduct a first-in-human trial to use PPM for the treatment of non-myoinvasive bladder cancer (NMIBC). This primary objective of the proposed Phase I trial is to determine the recommended Phase II dose (RP2D) of PPM. The secondary objectives are to assess the toxicity, obtain preliminary efficacy information of PPM, and determine systemic absorption after intravesical instillation of PPM. Up to 29 patients with recurrent or refractory NMIBC after a standard first-line intravesical BCG treatment will be recruited. PPM will be given as intravesical instillation once weekly for six weeks. The toxicity will be assessed by the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The efficacy will be determined by urine cytology and cystoscopy after finishing treatment. Molecular correlative studies will be performed.
General: Protect from light. Prolonged daily dose administration over 25,000 Units vitamin A should be under close supervision. Blood level assays are not a direct measure of liver storage. Liver storage should be adequate before discontinuing therapy. Single vitamin A deficiency is rare. Multiple vitamin deficiency is expected in any dietary deficiency.

Drug Interactions: Women on oral contraceptives have shown a significant increase in plasma vitamin A levels.

Carcinogenesis: There are no studies that show that administration of vitamin A will cause or prevent cancer.

Pregnancy: 

See CONTRAINDICATIONS section.

Nursing Mothers: The U.S. Recommended Daily Allowance (RDA) of vitamin A (5,000 Units) is recommended for nursing mothers.
<P>PROBLEM TO BE SOLVED: To develop a hyaluronic acid production promoter, promoting the production of hyaluronic acid, and effective for prevention of skin aging such as amelioration of rough skin, impartment of elasticity, tenseness and gloss to the skin, and amelioration of wrinkle and slack; and to obtain a composition for inducing beauty and homeostasis maintenance of an organism by a natural action of the organism by utilizing the promoter.  <P>SOLUTION: This hyaluronic acid production promoter contains a collagen peptide (Gly-X-Y)<SB>n</SB>(wherein, Gly is a glycine residue; X and Y are each an amino acid residue; and n is a positive integer) which is a degradation product of a collagen or a gelatin by a collagenase, and comprises a collagen tripeptide having an amino acid sequence represented by (Gly-X-Y). A skin care preparation for external use and a food and drink product contain the hyaluronic acid production promoter. As a result, the production of the hyaluronic acid is significantly promoted, and rough skin-ameliorating activities are provided. The skin care preparation for external use and the food and drink product containing the promoter have the skin aging-preventing effects such as the impartment of the tenseness and gloss, and the amelioration of the wrinkle and the slack.  <P>COPYRIGHT: (C)2004,JPO
Twenty participants in once a week group will receive acupuncture treatment 1 time per week for 4 weeks (Weekly fixed day), 4 sessions totally. Other inventions will be same as the Three times a week group.
A soluble film which dissolves in water without leaving undissolved lumps, has excellent meltability in the mouth, and is excellent in film properties including dryness resistance and nonblocking properties. Incorporating at least one member selected from the group consisting of Ϝ-polyglutamic acid and salts thereof into a film formed from a water-soluble polymer can give a soluble film greatly improved in meltability in the mouth and water solubility and less apt to decrease in moisture resistance and dryness resistance. Incorporating a gellant and/or a plasticizer into the soluble film can give an edible film having better film properties. The soluble film is used as a covering/packaging material or support for foods, medicines, cosmetics, etc. or as an edible filmy preparation containing any of various functional ingredients. In such applications, the film can have excellent film properties.
FIELD: medicine; pharmaceuticals; food industry.SUBSTANCE: invention refers to pharmaceutical and food industry, namely to an agent for inhibiting the formation of cell triglycerides in a subject. Composition for inhibiting the formation of cell triglycerides in a subject, comprising a mixture of extracts comprising a water-ethanol extract of whole grapes and, at least, one of water-ethanol extract of leaves and stems of hanibush and water extract of grape kernels in amount required for synergetic inhibition of cell triglycerides formation. Food product or beverage to reduce formation of cell triglycerides in a subject. Product for controlling weight. A method of treating, preventing or controlling an individual's weight gain. A method for reducing absorption, transport, sedimentation, production and secretion of fat in a subject. Method of facilitating body weight loss in a subject. A method for maintaining body weight of a subject. A method for treating, preventing or controlling skin conditions or diseases associated with skin fat production in a subject. Method of synergistic inhibition of diacylglycerol acyltransferase-1 (DGAT-I) in a subject.EFFECT: agents described above are effective for inhibiting the formation of cell triglycerides in a subject, for synergistic inhibition of diacylglycerol acyltransferase-1 (DGAT-I) in a subject.32 cl, 7 dwg, 1 tbl, 5 ex
Subjects randomized to spinal anesthesia will receive Bupivacaine 0.75%, 8-12.5 mg dose depending on estimated duration of surgery and anesthesiologist decision. In addition to spinal anesthesia, these subjects will possibly have concurrent administration of fentanyl, midazolam, and propofol so that they are mildy sedated or sleeping.
PURPOSE:To obtain an iron absorbing promoting agent containing a specific carboxylic acid type weakly acidic cation exchange resin as an active ingredient and capable of preventing and treating iron-deficient state such as anemia by promoting absorption of iron content in a food by oral administration. CONSTITUTION:A carboxylic acid type weakly acidic cation exchange resin (e.g. 'Amberlite(R) IRP-64') containing a giant net structure as mother constituent is added as an active ingredient and prepared singly or using a crude matter for preparation according to an ordinary method to provide aimed product. The aimed product can be prepared in form of oral administration of tablet, ointment, inhalant, liquid medicine, suspension, emulsion, granule, capsule, etc. An active ingredient amount contained in the preparation is preferably normally >=40wt.% in medicine preparation. The dose is 50-300mg/kg daily.
The morphometric characteristics of brain tissue were studied based on autopsy material from 49 deceased newborns divided into 7 groups based on the time after death. Samples were taken from the upper (frontal lobe) and lower (occipital lobe) regions relative to the supine position of the body. Paraffin sections were prepared from these samples and stained with hematoxylin and eosin. Histological preparations were analyzed using an image analysis system to determine the area of gliocyte nuclei, cross-cut blood vessels, and expanded area around them in the white matter of the brain. Based on these data, severity indices were calculated for both cellular (pericellular) and vascular (perivascular) expansion. The dynamics of changes in morphometric parameters within the range of cellular and vascular alterations on brain tissue specimens, which reflect the development of postmortem hypostasis and autolysis in this organ, can be used to estimate the duration of the postmortem interval. At the same time, these changes, when combined with other non-specific postmortem findings, should be distinguished from long-term pathological processes and diseases that may have occurred during life.
The investigators are studying the elderly population who have prefrailty (Fried Frailty). Participants include those who are: a) Aged 65 to 100 years old b) screened CFS 3-4 with prefrailty in Fried Frailty Criteria. Patients will be approached via phone call by care coordinators, as part of the routine care. As part of the routine care to our chronic patients, care coordinators identify eligible patients for annual screening to update personal particulars/ cancer screening and vaccination statuses as per the Healthier SG program before patient's chronic disease appointment. Also as part of the routine care, care coordinators will screen for CFS 3 and 4 patients over the phone. Patients who fulfil CFS 3 and 4 will be arranged to have a physical consultation with care coordinators on their day of prescheduled visit in the clinic. Patients meeting the eligibility criteria for the study, will be approached by the care coordinator to ask for research interest. If interested in participating, patients will be referred to the research team member for secondary screening after pre-screening informed consent is taken. Participants who fulfil prefrailty in Fried Frailty criteria will be recruited and consent will be taken. Participants will then be randomly assigned to "intervention" or "usual care" parallel arms. Randomisation of participants will be done on 1:1 allocation to intervention or usual care by a simple randomisation procedure. Participants randomly assigned to the usual care group will receive normal primary care, including dietitian and physiotherapy services if needed. Intervention participants will receive the described intervention on top of usual care. Intervention participants will be taught specific resistance and balance exercises and participants will receive a leaflet with pictorial guide on the home based exercise regime. The participants will be advised to consume adequate protein and participants will also receive another leaflet on protein consumption as part of a balanced diet. At the 3 month and 12 month mark, participants in the intervention group will see the care coordinator who will assess compliance and re-enforce the exercise regime and dietary protein intake counselling, and check for any difficulties faced.
Exercise training is a valuable tool for improving body weight and composition in overweight or obese adults, which leads to a negative energy balance. It is relevant to consider whether exercise can help people lose weight or prevent weight gain because any energy expended in exercise increases the severity of hunger and promotes food consumption. Over the past decade, the identification of the circulating peptide ghrelin, which alerts the brain to the body's nutritional state, has significantly expanded our understanding of this homeostatic mechanism that controls appetite and body weight. To shed more light on this issue, we decided to investigate the effects of resistance and endurance training on plasma ghrelin and leptin levels. In addition, we sought to understand the mechanisms by which acute and chronic exercise can regulate hunger. This review analyzes studies published in the last fifteen years that focused on changes suffered by ghrelin, leptin, or both after physical exercise in overweight or obese individuals. Most studies have shown a decrease in leptin levels and an increase in ghrelin levels in these cases. Exercise regimens that support weight maintenance need further investigation.
<P>PROBLEM TO BE SOLVED: To obtain a new osteoclastogenesis inhibitory factor (OCIF) and provide a method for efficiently producing the same.  <P>SOLUTION: A protein having activity for inhibiting differentiation and/or maturity of osteoclast is obtained and a method for producing the same is provided. The protein is produced with Homo sapiens foetal pulmonary fibroblasts and has about 60 KD molecular weight in a reducing condition and about 120 KD molecular weight in a non-reducing condition. The protein is isolated and purified from a culture solution of the fibroblast cells. The protein is also produced in genetic engineering. The invention includes cDNA for genetic engineering production, an antibody expressing specific affinity for the protein and a method for determining the protein by using the antibody.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
BACKGROUND AND AIM: Tight junctions maintain gut homeostasis by forming a physical barrier that protects the gut from invasion by microbiota. Cldn-7 is an important component involved in this protection, but the relationship between Cldn-7, intestinal inflammation, and gut microbiota has not been clarified. Here, we hypothesize that Cldn-7 depletion affects intestinal inflammation by altering the gut microbiota.
METHODS: Based on the induced intestinal condition of Cldn-7 knockout mice (Cldn7fl/fl;villin-CreaERT2), we established the intestinal flora depletion model and colitis model by antibiotic drinking and feeding with dextran sodium sulfate (DSS). The environment of Cldn-7 gene deletion mice was changed by co-housing experiment. AB-PAS staining and Muc2 were used to detect the effect of co-housing and Cldn-7 deficiency on the mucus layer after flora depletion. qRT-PCR was used to detect the expression of intestinal inflammatory factors and AMPs in mice. Feces were collected and proportions of microbiota were analyzed by 16 S rRNA amplicon sequencing.
RESULTS: Mice in the co-housing experiment had altered intestinal microbiota, including diversity, composition, and functional prediction, compared to controls. Intestinal inflammation was restored to some extent following altered intestinal microbiota. The intestinal inflammation caused by Cldn-7 deficiency and susceptibility to DSS could be reduced after antibiotic administration compared to controls, in terms of phenotype, pathological changes, inflammatory factors, mucus barrier, and expression of AMPs.
CONCLUSIONS: In analyses of intestinal tissues, colitis induction, and gut microbiota in mice with intestinal disruption of Cldn-7, we found this protein to prevent intestinal inflammation by regulating the gut microbiota. Cldn-7might therefore be an important mediator of host-microbiome interactions. Our research has revealed that Cldn-7 plays an indispensable role in maintaining intestinal homeostasis by regulating the gut microbiota and impacting intestinal inflammation. These findings provide new insights into the pathogenesis of ulcerative colitis.
This invention relates to the field of the technology of the Chinese traditional medical preparation. It has specially revealed A Chinese traditional medicinal preparation for treating cardiovascular stasis coronary heart disease and its' preparing method. The medicine is a kind of thin filmed tablets, which through distilling and purifying from radices paeoniae rubra to be active components, then add right volume of the medical supplementary materials, make it into tablet form through pressure and coated with thin film. Indications of pharmacological researches show this medicine has the characters of small dosage, light side effects and high biologic utilization. It also has the performance of promoting blood circulation, eliminating purulence, relieving pain and making meridian through, obviously reducing symptom of myocardial ischemia due to coronary artery ligature, minimizing the scale of myocardial infarct, lowing down the elevation degree of LDH blood sera, protecting those cell of cardiac muscle that ischemia. Result of virulence research shows that even taking 10 times of the preferred medical dosage did not occur virulence reflection.
Children are placed in this arm if they screen positive for EED using the urinary lactulose:mannitol (L:M) recovery ratio. Children will receive a one-time 3 mg standard dose of zinc sulfate with stable isotope zinc tracer and 0.5 mg standard dose of 13C10-retinyl-acetate (vitamin A isotope).
The logging and monitoring of bowel movements and urinary events is an important aspect of preventative care for residents in senior living facilities, providing early warning signs for conditions that may otherwise cause complications if dealt with reactively. However, this information is sporadically collected - if at all - and subjectively interpreted by caregivers, leading to inconsistencies and unreliable data. Toi Labs, Inc. has created TrueLoo™, an Internet-connected toilet seat, as a solution to these issues. TrueLoo™ acquires time-lapse images of a bowel movement or urinary event automatically and under controlled conditions. Residents enrolled in the current study will have a TrueLoo™ installed in their private bathroom, through which all bowel movements and urinary events will be tracked, anonymously, privately, and securely. As a result, an electronic bowel movement and urinary event log for each enrolled resident will be generated. Given sufficient data, the TrueLoo™ system will complete such electronic logs automatically, identify points in time where particular enrolled residents may have experienced anomalous toileting patterns, and determine the relevance of such events through targeted health history and urine sampling.